Sam Fazeli
speaker
906 appearances
5 recordings
1 series
first heard Oct 2025
last heard 31 Mar
Sam Fazeli’s voice in public audio — every appearance, attributed to the second.
Trend
recordings per month · last 12 monthsRecordings per month over the last 12 months — 5 in all, peaking in Mar 2026 with 2.
Appearances
I mean, you've definitely thrown the dice.
seriously on rivagostomig and you could say volarostomig too.
You know, I don't know.
I think we talked about this last time.
I counted something like 8,000 patients in total in the various rivagostomig trials.
I am hopeful.
I believe in your translational data.
That was beautiful to see at WCLC.
And of course I missed this time last year's CITSE presentation, but fingers crossed because I think it would be finally changing people's attitudes to more than
lag 3 and ctl a4 in single agent um or combo so
Just to touch on bladder cancer, non-muscle invasive bladder cancer.
Potomac trial delivered good EFS results, 0.68 in BCG-naive high-risk non-muscle invasive bladder cancer, which of course is a key thing there is to preserve the bladder, is what everybody tries to do with a variety of mechanisms.
Very similar to the Pfizer CREST study and trial design, but Infinzi is used for one year
versus Sazanlimab for two years.
And Potomac showed earlier EFS curve separation that was at about three months and crest.
Do you want to just talk to us about this comparison I'm making, which is, again, not head-to-head, of course, and also what it means for the role of Mfinzine in non-muscle-invasive bladder cancer, especially patients with Sari, this particular type of it, which is carcinoma in situ.
Yeah.
So just let me move on quickly to, thank you for that.
The other data set we saw from Combo that seems to be doing very well in the setting.
So this is the non-metastatic MIBC.
Showing 841–860 of 906 · page 43 of 46
← Previous
Next →